Blockchain Registration Transaction Record

Annovis Bio Secures $10M Funding, Extends Runway Through 2027 for Neurodegenerative Drug

Annovis Bio raises $10M in public offering, extending cash runway through 2027 to advance buntanetap for Alzheimer's and Parkinson's disease treatment during critical Phase 3 trial period.

This development matters because neurodegenerative diseases like Alzheimer's and Parkinson's affect millions worldwide with limited treatment options that primarily address symptoms rather than underlying causes. Annovis Bio's buntanetap represents a potentially transformative approach targeting multiple neurotoxic proteins simultaneously, which could slow or halt disease progression rather than just managing symptoms. The extended financial runway through 2027 provides crucial stability for the company to complete its Phase 3 Alzheimer's trial and prepare for FDA submission, reducing the risk of development delays due to funding shortages. For patients and families affected by these devastating conditions, successful development of buntanetap could mean preserved cognitive and motor function and improved quality of life. For the broader medical community, it represents progress toward disease-modifying treatments that address the complex pathology of neurodegeneration.